Vildagliptin shows diabetes benefits but raises CV concerns

05/28/2013 | MedPage Today (free registration)

A study presented at the Heart Failure Congress found type 2 diabetes patients with heart failure who took vildagliptin attained lower A1C levels at 16 weeks compared with those in the placebo group. However, researchers noted higher rates of cardiovascular and all-cause mortality in vildagliptin-treated patients.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT